ACAB · Atlantic Coastal Acquisition Corp. II - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $13.0K | - | $642.0K | $827.0K | $1.00M | - | - | - | - | - |
| SG&A | $920.0K | - | $1.09M | $1.51M | $1.88M | - | - | - | - | - |
| Total Operating Expenses | $933.0K | - | $2.11M | $2.26M | $2.88M | - | $260.0K | - | - | - |
| D&A | $8.0K | - | - | $6.0K | $50.0K | - | - | - | - | - |
| Operating Income | ($933.0K) | - | ($1.34M) | ($2.26M) | ($2.96M) | - | ($391.7K) | ($393.7K) | ($1.14M) | - |
| Interest Expense | $23.0K | - | $193.0K | $174.0K | $42.0K | - | $127.6K | - | - | - |
| Income Tax | - | - | - | - | - | - | $27.7K | $26.2K | $4.1K | - |
| Net Income | ($1.03M) | - | ($1.66M) | ($2.98M) | ($3.89M) | - | ($335.1K) | ($338.9K) | ($1.05M) | - |
| EPS - Basic | ($0.23) | - | ($3.27) | ($0.05) | $0.02 | - | - | - | - | - |
| EPS - Diluted | ($0.23) | - | ($3.27) | ($0.13) | $0.01 | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.41M | $82.0K | $343.0K | $2.03M | $1.41M | $2.85M | $13.6K | $236.8K | $10.6K | $264.5K |
| Accounts Receivable | $183.0K | $183.0K | $271.0K | $342.0K | $331.0K | $323.0K | - | - | - | $88.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.95M | $5.32M | $4.72M | $5.27M | $4.70M | $3.94M | - | - | - | $7.92M |
| Current Assets | $6.70M | $896.0K | $1.23M | $3.07M | $2.22M | $3.78M | $1.56M | $277.3K | $25.8K | $29.99M |
| Total Assets | $6.87M | $1.06M | $1.70M | $3.48M | $2.80M | $4.66M | $7.86M | $7.90M | $7.53M | $37.37M |
| Current Liabilities | $9.12M | $9.35M | $17.30M | $20.43M | $20.61M | $19.61M | $9.04M | $7.31M | $6.61M | $35.39M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | $19.61M | $19.54M | $17.81M | $17.11M | $45.89M |
| Stockholders' Equity | ($2.80M) | ($8.83M) | ($16.14M) | ($17.50M) | ($18.36M) | ($15.49M) | ($17.81M) | ($17.40M) | ($16.99M) | ($15.82M) |
| Retained Earnings | ($120.02M) | ($119.00M) | ($124.63M) | ($122.97M) | ($119.99M) | ($116.10M) | ($17.81M) | ($17.40M) | ($16.99M) | ($15.82M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.08M) | - | - | - | ($1.72M) | - | - | - | ($263.9K) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | $29.69M | - |
| Financing Cash Flow | $7.41M | - | - | - | $132.0K | - | - | - | ($29.68M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -15.0% | - | -97.3% | -85.7% | -139.0% | - | -4.3% | -4.3% | -13.9% | - |
| Return on equity | 36.7% | - | 10.3% | 17.1% | 21.2% | - | 1.9% | 1.9% | 6.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.74 | 0.10 | 0.07 | 0.15 | 0.11 | 0.19 | 0.17 | 0.04 | 0.00 | 0.85 |
| Quick ratio | 0.74 | 0.10 | 0.07 | 0.15 | 0.11 | 0.19 | 0.17 | 0.04 | 0.00 | 0.85 |
| Cash ratio | 0.59 | 0.01 | 0.02 | 0.10 | 0.07 | 0.15 | 0.00 | 0.03 | 0.00 | 0.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -40.6x | - | -6.9x | -13.0x | -70.4x | - | -3.1x | - | - | - |
| Equity multiplier | -2.45 | -0.12 | -0.11 | -0.20 | -0.15 | -0.30 | -0.44 | -0.45 | -0.44 | -2.36 |
| Liabilities / Assets | - | - | - | - | - | 4.21 | 2.49 | 2.26 | 2.27 | 1.23 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 68.5% | - | -241.1% | -474.3% | -159.2% | - | -24.2% | 6.3% | -112.3% | - |
| Net income growth (YoY) | 73.6% | - | -394.5% | -780.6% | -270.6% | - | -650.8% | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 84.7% | 43.0% | 9.4% | -0.6% | -8.1% | 2.0% | -18.3% | -17.5% | -45.6% | -41.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$183.0K totalResearch And Development Services$183.0K · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Atlantic Coastal Acquisition Corp. II against the 5 most active filers in the same SIC group.